Astrazeneca Share News (AZN)

AstraZeneca breast cancer drug granted priority review by US FDA

(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Enhertu metastatic breast cancer asset had been granted priority review status in the US following results from its DESTINY-Breast04 trial.

AstraZeneca breast cancer drug granted priority review by US FDA

(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Enhertu metastatic breast cancer asset had been granted priority review status in the US following results from its DESTINY-Breast04 trial.

UK earnings, trading statements calendar - next 7 days

As COVID patent war rages on, pharma group seeks fairer future access

LONDON, July 19 (Reuters) - An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for COVID-19 interventions between the pharmaceutical industry and developing nations endures.

TOP NEWS: AstraZeneca breast cancer drug wins approval in EU

(Alliance News) - AstraZeneca PLC on Tuesday said a breast cancer drug developed with Tokyo-based partner Daiichi Sankyo Co Ltd has been approved in the European Union.

AstraZeneca's HER2-positive breast cancer drug receives EU approval

(Sharecast News) - Drugmaker AstraZeneca's Enhertu has received European Union approval to be used as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.

UK stocks end the week lower as slowdown woes mount

July 15 (Reuters) - London's FTSE 100 index ended the week lower on worries about aggressive interest rate hikes and a sharp slowdown in the global economy, even as energy and defensive stocks lifted the benchmark index more than 1% on Friday.

IN BRIEF: Hutchmed presents solid results from lung cancer study

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Presents positive results from the Savannah phase two trial of Hutchmed and AstraZeneca PLC's savolitinib in combination with Astra's osimertinib in epidermal growth factor receptor-mutated non-small cell lung cancer patients.

LONDON BROKER RATINGS: RBC, Goldman, Jefferies review property shares

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

LONDON BROKER RATINGS: Berenberg cuts Rio Tinto and BofA lowers Anto

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Weak sterling boosts FTSE 100 amid political, growth worries

July 6 (Reuters) - UK stock markets on Wednesday rebounded from a sharp sell-off, with exporter-heavy FTSE 100 benefiting from a weakness in sterling as economic worries were compounded by a crisis in Boris Johnson's government.

China allows AstraZeneca's COVID preventive drug in southern city

BEIJING, July 6 (Reuters) - AstraZeneca Plc's antibody cocktail for COVID-19 prevention has been cleared for use in a medical tourism zone in China's southern province of Hainan ahead of national approval, local media said on Tuesday.

AstraZeneca to buy biotech firm TeneoTwo for up to $1.27 bln

July 5 (Reuters) - AstraZeneca agreed to acquire biotechnology firm TeneoTwo Inc in a deal worth up to $1.27 billion on Tuesday, in a move to bolster its roster of therapies to treat blood cancers.

LONDON MARKET PRE-OPEN: Sainsbury's backs outlook; AstraZeneca buys

(Alliance News) - Stock prices in London are seen opening higher on Tuesday, continuing a somewhat confident start to the third quarter for equities, despite inflationary and recessionary fears showing little sign of fading.

AstraZeneca agrees to acquire TeneoTwo

(Sharecast News) - Drugmaker AstraZeneca has agreed to acquire TeneoTwo and its clinical-stage T-cell engager in a deal worth up to $1.26bn as part of an effort to accelerate the development of the potential new medicine for B-cell haematologic malignancies.